Protalix BioTherapeutics, Inc. Q2 2025 Earnings Recap

Protalix BioTherapeutics reported a robust 50% year-over-year increase in Q2 2025 revenues, driven by strong sales of its Fabry disease treatment, Elfabrio, through its partner Chiesi.

Key Takeaways

• Revenues from selling goods reached $15.4 million, reflecting a 16% increase from Q2 2024, primarily due to Elfabrio sales.
• Protalix anticipates Elfabrio royalties will exceed $100 million by 2030, targeting a 15%-20% market share in the $3.2 billion Fabry market.
• The company is progressing toward a Phase II study for its gout treatment candidate, PRX-115, expected to commence in late 2025.
• Chiesi's ongoing investments and focus on Elfabrio position Protalix favorably for future growth in the rare disease sector.
• Eyal Rubin is stepping down as CFO, succeeded by Gilad Mamlok, marking a transition in financial leadership as the company aims for continued advancement.